Key Highlights
● Co-Diagnostics failed to reach quorum at its annual meeting on both September 3 and September 24, 2026.
● The meeting was adjourned a third time to September 30, 2026 at 9:00 a.m. Mountain Time in Salt Lake City.
● Proxies already submitted by shareholders remain valid for the reconvened meeting unless affirmatively revoked.
● Repeated quorum failures are uncommon on Nasdaq and often reflect low turnout among a fragmented retail Shareholder base.
Co-Diagnostics (NASDAQ:CODX), a Salt Lake City-based molecular diagnostics company, disclosed in an 8-K that its annual shareholders meeting has now failed to reach quorum twice, forcing the company to adjourn the meeting a third time to September 30, 2026.
A Meeting Adjourned Twice
The 8-K, filed under Item 5.07, Submission of Matters to a Vote of Security Holders, states that Co-Diagnostics' annual meeting first convened on September 3, 2026, but "the Company did not achieve a quorum and therefore was unable to transact Business at the meeting." The meeting was adjourned and reconvened on September 24, 2026, but again failed to reach quorum. As a result, the meeting was adjourned a third time, to September 30, 2026 at 9:00 a.m. Mountain Time, to be held at 2401 S. Foothill Dr, Ste. D, Salt Lake City, Utah.
How the Company Can Keep Adjourning
The filing notes that under the company's bylaws, "the chairperson of the meeting has the power to adjourn the meeting from time to time" without the need for additional notice to shareholders once a meeting has been properly convened, which is the mechanism Co-Diagnostics has relied on to move the meeting from September 3 to September 24 and now to September 30. The filing does not specify the exact quorum percentage required under the company's bylaws, but the repeated failures indicate that not enough shares, whether held directly or through brokers, were represented at either of the first two sessions to meet that threshold.
What Happens to Existing Votes
Importantly, the 8-K states that proxies already submitted by shareholders ahead of the earlier meeting dates remain valid for the September 30 reconvened meeting unless a shareholder affirmatively revokes their proxy beforehand. This means shareholders who already voted do not need to resubmit their votes for the meeting to proceed once quorum is eventually reached, though it also means the company is relying on previously cast votes rather than fresh turnout to finally cross the quorum threshold.
Co-Diagnostics develops molecular diagnostic technology, including its CoPrimer platform used in tests for infectious diseases. The 8-K itself does not include further description of the company's current business operations or financial position, focusing solely on the meeting adjournment. Repeated quorum failures of this kind are relatively uncommon among Nasdaq-listed companies and often reflect low shareholder turnout combined with a highly fragmented or largely retail shareholder base, where many holders do not return proxy cards even for routine matters.
What the Filing Does Not Say
The filing does not disclose what percentage of shares was represented at either failed attempt, nor does it state the specific quorum threshold set by Co-Diagnostics' bylaws that has twice gone unmet. It also does not address what business items are on the agenda for the eventual meeting, such as director elections or auditor ratification, or whether the company has taken any additional steps, such as expanded proxy solicitation, to secure quorum before September 30. The filing does not mention any engagement with a proxy solicitation firm or other outreach effort undertaken between the September 3 and September 24 sessions to try to boost turnout.
A Third Attempt on September 30
The reconvened meeting is now scheduled for September 30, 2026 at 9:00 a.m. Mountain Time, to be held at the company's Salt Lake City address; investors should watch for whether Co-Diagnostics finally achieves quorum on that date or is forced to adjourn for a fourth time, which would extend the delay in transacting the meeting's business even further and could prompt additional disclosure about the company's efforts to secure shareholder participation.



_11_17_2026_20_37_58_946960.jpg)


Please wait processing your request...